|Mr. Daniel Mark Bradbury||CEO & Chairman||315k||N/A||1961|
|Dr. Stephen Connelly||Chief Scientific Officer & Director||373.75k||N/A||1982|
|Dr. Krishna R. Polu||Chief Medical Officer||419.75k||N/A||1973|
|Mr. Bruce D. Steel C.F.A.||Co-Founder, Pres, Chief Bus. Officer & Director||N/A||N/A||1966|
|Mr. Jason A. Keyes||Chief Financial Officer||N/A||N/A||1971|
Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.
Equillium, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.